Tumor protein p53–MDM4 interaction (p53–MDM4)

The **p53/MDM4 interaction** is a critical regulatory checkpoint in cellular homeostasis. p53 is a transcription factor that induces cell cycle arrest or apoptosis in response to DNA damage or oncogenic stress. MDM4 (MDMX) binds directly to the N-terminal transactivation domain of p53, repressing its transcriptional activity and, in conjunction with MDM2, can promote p53 degradation[1][2][3]. MDM4 does not have intrinsic E3 ubiquitin ligase activity but enhances the E3 ligase function of MDM2 via heterodimerization, amplifying p53 ubiquitination and degradation[3]. Overexpression or amplification of MDM4 in human cancers leads to p53 inhibition and proliferation of tumor cells. Pharmacological disruption of the p53–MDM4 interface is an active area of anticancer drug development, aiming to reactivate p53 function specifically in tumors with wild-type p53 and MDM4 overexpression[4]. Experimental small molecules and peptides are in development to block the p53–MDM4 interaction, either alone or together with p53–MDM2 inhibition, to release p53 from negative regulation, thus restoring its tumor suppressor capacity in cancer cells[3][4].

Other names

p53–MDMX interactionTP53–MDM4 interactionp53–MDM4 complexp53–MDMX binding

Inhibitors block the interaction between p53 and MDM4, releasing p53 from repression, leading to activation of its tumor suppressor functions (cell cycle arrest, apoptosis). MDM4–MDM2 heterodimer inhibition: Promotes p53 restoration by destabilizing the suppression complex and activating a p53-dependent cellular response[4].